Previous 10 | Next 10 |
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Introduction: On June 21st, 2019, the second ever treatment for hypoactive sexual desire disorder (HSDD) in women was approved by the FDA. The drug, Bremelanotide (Referred in the article as "Bremo" /" Vyleesi") was developed as a combined R&D effort between Palatin Technologies ( PTN ...
Amag Pharmaceuticals (NASDAQ: AMAG ) is up 11.5% postmarket, and Palatin Technologies (NYSEMKT: PTN ) is up 42.6% , following FDA approval for their Vyleesi treatment for low libido in women. More news on: AMAG Pharmaceuticals, Inc., Palatin Technologies, Inc., Top stock market news, ...
The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Distress or Interpersonal Difficulty Due to Low Sexual Desire 1 in 10 Premenopausal Women in the U.S. (Approximately 6 Million Women) Suffer From HSDD WALTHAM, Mass., June 21, 2019 (GLOBE NEWSWIRE) -- AM...
Amag Pharmaceuticals ( AMAG +4.4% ) and Palatin Technologies ( PTN -3.9% ) are moving in opposite directions on the last trading day ahead of Sunday's FDA decision date on Vyleesi, the latest drug compared to a "female Viagra." More news on: AMAG Pharmaceuticals, Inc., Palatin Technolo...
Introduction: AMAG Pharmaceuticals ( AMAG ) is a specialty pharmaceuticals company with an emphasis on Women's Health and treatment of Iron Deficiency Anemia. The company's stock has been punished over the past quarter due to the presence of generics taking market share from its key produ...
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by AMAG Pharmaceuticals, Inc. in conjunction with this Read more ...
Introduction: The availability of peptide drugs is still limited All or most all of the FDA approved and commercially available drugs are targeting proteins . In the natural environment, these proteins can be stimulated by small molecules, peptides, and other proteins. However, while the fi...
WALTHAM, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Wednesday, June 5, 2019 at 3:00 p.m. EDT....
News, Short Squeeze, Breakout and More Instantly...
AMAG Pharmaceuticals Inc. Company Name:
AMAG Stock Symbol:
NASDAQ Market:
AMAG Pharmaceuticals Inc. Website:
WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to withdraw approval for Makena—also referred to as 17-OHP...
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena ® , the only F...